Core Insights - Asure has appointed Jay Whitehead to lead its AsurePay™ Platinum VIP Banking card and Marketplace businesses, aiming to enhance its offerings in the Human Capital Management (HCM) sector [1][3]. Company Overview - Asure is a provider of cloud-based HCM software solutions that streamline HR processes for organizations of all sizes, including services like payroll, time and attendance, benefits administration, and talent management [5]. Leadership Background - Jay Whitehead has a rich background in HR and payment technology, having founded Human Resources Outsourcing Today and led various media and HR companies, which positions him well to drive Asure's initiatives [2]. Market Opportunity - Asure's payroll clients, representing nearly two million employees, have expressed a strong interest in the AsurePay™ Platinum VIP Banking card, which offers features superior to those of cards requiring $75,000 deposit minimums [3]. - The Asure Marketplace is seen as a valuable resource for companies to provide financial and consumer products to Asure's largely untapped payroll base [4].

落袋为安。 作者 I 岳笑笑 报道 I 投资界PEdaily 李嘉诚罕见出手。 近日，上市公司和黄医药发布公告，宣布以6. 0 8亿美元（约合人民币4 5亿元）现金向上 海金浦健服股权投资管理有限公司（简称"金浦健服投资管理"）和上海医药集团股份有 限公司（简称"上海医药"）出售其在上海和黄药业有限公司（简称"和黄药业"）的4 5%的 股权。 时间回到2 0 0 1年，李嘉诚所掌舵的和黄医药联手上海医药成立上海和黄药业，开启"中药 梦"。2 0年一晃而过，这一笔投资无疑带来丰厚回报。在此节点，李嘉诚选择落袋为安。 公告显示，交易设有三年的过渡期。在此期间，上海和黄药业的总经理将由和黄医药推 荐，并向金浦健服投资管理保证上海和黄药业净利润至少每年约 5%的增长，但补偿总额 不超过约 9, 500万美元。 交易完成后，上海医药将合计持有和黄药业60%股权，成为其实控人并对其并表。和黄医 药预期将录得除税前出售收益约4.77亿美元，并保留其持有的5%间接股权。 说起来，和黄药业与李嘉诚渊源深厚。资料显示，2 0 01年公司由上海医药全资子公司上 海市药材有限公司与和黄医药合资设立，双方各持股5 0%。其中，和黄医药 ...

Core Viewpoint - The article discusses the investment outlook for Paycor HCM (NASDAQ: PYCR), indicating a downgrade to a hold rating due to concerns about its growth potential [3]. Group 1: Company Analysis - Paycor HCM has been downgraded to a hold rating based on the analyst's lack of confidence in its ability to achieve growth [3]. - The investment approach focuses on identifying companies with solid fundamentals and sustainable competitive advantages, which is critical for long-term investment success [2]. Group 2: Investment Strategy - The investment strategy incorporates both long-term investments and short-term shorts to uncover alpha opportunities, emphasizing a bottom-up analysis of individual companies [2].

Core Viewpoint - Robbins LLP is investigating Paycor HCM, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] Company Overview - Paycor HCM, Inc. provides human capital management solutions primarily for small and medium-sized businesses in the United States [1] Legal Context - Shareholders who have lost money in their investment in Paycor HCM, Inc. are encouraged to contact Robbins LLP for information about their rights [2] - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [3] Firm Background - Robbins LLP has been active in shareholder rights litigation since 2002, recovering over $1 billion for shareholders [4]

Core Insights - HUTCHMED will receive a US$10 million milestone payment from Takeda following the first national reimbursement recommendation for FRUZAQLA® (fruquintinib) in Europe for metastatic colorectal cancer [1][2] - FRUZAQLA® is the first novel oral targeted therapy approved in the EU for metastatic colorectal cancer in over a decade, with its European Commission approval granted in June 2024 [2][3] - The approval is based on the Phase III FRESCO-2 trial results, which demonstrated consistent benefits for patients treated with fruquintinib [3][6] Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [7] - The company has approximately 5,000 personnel, with a significant focus on oncology and immunology [7] - HUTCHMED's fruquintinib has been co-marketed in mainland China, Hong Kong, and Macau under the brand name ELUNATE® in collaboration with Eli Lilly and Company [6] Industry Context - Colorectal cancer (CRC) is the third most prevalent cancer globally, with over 1.9 million new cases and 900,000 deaths reported in 2022 [4] - In Europe, CRC accounted for approximately 538,000 new cases and 248,000 deaths in 2022, highlighting the significant unmet medical need in this area [4] - The approval and reimbursement of FRUZAQLA® represent a critical advancement in treatment options for patients with metastatic CRC, particularly given the poor outcomes associated with this condition [4][5]

Core Insights - HUTCHMED will receive a US$10 million milestone payment from Takeda following the first national reimbursement recommendation for FRUZAQLA® (fruquintinib) in Europe for metastatic colorectal cancer [1][2] - FRUZAQLA® is the first novel oral targeted therapy approved in the EU for metastatic colorectal cancer in over a decade, with its European Commission approval granted in June 2024 [2][3] - The approval was based on the Phase III FRESCO-2 trial results, which demonstrated consistent benefits for patients treated with fruquintinib [3][6] Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [7] - The company has approximately 5,000 personnel, with a significant focus on oncology and immunology [7] - HUTCHMED's fruquintinib has been co-marketed in mainland China, Hong Kong, and Macau with Eli Lilly under the brand name ELUNATE® [6] Industry Context - Colorectal cancer (CRC) is the third most prevalent cancer globally, with over 1.9 million new cases and 900,000 deaths reported in 2022 [4] - In Europe, CRC accounted for approximately 538,000 new cases and 248,000 deaths in 2022, highlighting the significant unmet medical need in this area [4] - The approval of FRUZAQLA® is expected to improve patient access to innovative treatments for metastatic CRC across Europe [3]

Core Insights - HUTCHMED's combination therapy of ORPATHYS® and TAGRISSO® has received Breakthrough Therapy Designation from China's NMPA for treating advanced or metastatic EGFR mutation-positive NSCLC with MET amplification after progression on EGFR inhibitors [1][3] Company Overview - HUTCHMED is an innovative biopharmaceutical company focused on developing targeted therapies and immunotherapies for cancer and immunological diseases, employing approximately 5,000 personnel [15] - The company has a collaboration with AstraZeneca for the global development and commercialization of ORPATHYS®, with HUTCHMED leading development in China [12] Drug Development and Trials - The ongoing Phase III SACHI trial is evaluating the efficacy and safety of the ORPATHYS® and TAGRISSO® combination against standard platinum-based chemotherapy in NSCLC patients with MET amplification [2][8] - ORPATHYS® has been conditionally approved in China for patients with MET exon 14 skipping alterations and is included in the National Reimbursement Drug List since March 2023 [9] - The combination has shown promising results in previous studies, leading to the initiation of multiple Phase III trials, including SANOVO and SAFFRON [5][8] Disease Context - Lung cancer is the leading cause of cancer death, with NSCLC accounting for 80-85% of cases; approximately 30-40% of NSCLC patients in Asia have EGFR mutations [4] - MET amplification is a significant mechanism of resistance to EGFR TKIs, with 15-50% of patients experiencing disease progression post-osimertinib presenting with MET aberration [4][10]

Core Insights - The New Drug Application for the combination of fruquintinib and sintilimab has received conditional approval in China for treating advanced endometrial cancer patients with pMMR tumors who have failed prior systemic therapy and are not candidates for curative surgery or radiation [1][2][3] Company Insights - HUTCHMED and Innovent Biologics are collaborating on the development of fruquintinib and sintilimab, with HUTCHMED focusing on extending the clinical benefits of fruquintinib to a broader patient population [3][15] - Innovent aims to provide innovative treatment options that improve survival rates and quality of life for patients with advanced endometrial cancer [3][16] Clinical Study Insights - The approval was supported by data from the FRUSICA-1 study, which showed an objective response rate (ORR) of 35.6% and a disease control rate (DCR) of 88.5% for the combination therapy [2] - The median progression-free survival (PFS) and overall survival (OS) were reported at 9.5 months and 21.3 months respectively, indicating promising efficacy [2][3] Market Context - Endometrial cancer remains a significant global health challenge, with approximately 417,000 diagnoses and around 97,000 deaths reported in 2020 [6] - In China, there were an estimated 82,000 new cases of endometrial cancer in 2020, highlighting the unmet need for effective treatments in this area [6] Product Insights - Fruquintinib is a selective oral inhibitor of all three VEGF receptors, designed to inhibit tumor angiogenesis and enhance selectivity [7] - Sintilimab, marketed as TYVYT®, is a PD-1 monoclonal antibody that reactivates T-cells to kill cancer cells and has multiple approved indications in China [11][12]

Core Viewpoint - HUTCHMED announces the renewal of the contract with the China National Healthcare Security Administration, ensuring that ORPATHYS® will remain on the National Reimbursement Drug List effective January 1, 2025, under the same terms as the previous agreement [1]. Group 1: Product Information - ORPATHYS® (savolitinib) is a selective MET tyrosine kinase inhibitor approved in China for treating non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations [2][5]. - The drug was first included in the National Reimbursement Drug List on March 1, 2023, highlighting the Chinese government's focus on improving drug affordability [3]. - ORPATHYS® is jointly developed by HUTCHMED and AstraZeneca, and it is the first selective MET inhibitor approved in China and included in the NRDL [5]. Group 2: Market Context - As of the end of 2023, approximately 1.33 billion people in China had basic medical insurance, covering around 95% of the population, which supports the market potential for ORPATHYS® [3]. - The NRDL is updated annually, and the inclusion of drugs is subject to a renewal process every two years, indicating a structured approach to drug reimbursement in China [3]. Group 3: Clinical Development - ORPATHYS® has shown clinical activity in advanced solid tumors and is currently under development for multiple tumor types, including lung, kidney, and gastric cancers [4][5].

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA® (fruqui ...